Albers Jeffrey W. sold $1.9M of SYRE (indirect holdings)
Albers Jeffrey W. sold 18,000 indirectly-held shares of Spyre Therapeutics, Inc. (SYRE) at an average of $104.55 ($104.38–$104.68, $1.88M total) across 2 trades on 2026-08-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market sale details (shares, price range, total value) executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity, but this specific disclosure is unlikely to drive a major repricing given the 10b5-1 structure.
What to watch
The filing does not disclose reasons for the sale, and the net holdings after the transaction (9,360 shares) may still be meaningful for the director’s overall exposure.
Background
The article is an SEC Form 4 insider transaction disclosure for Spyre Therapeutics, Inc. (SYRE).
Ticker impact
Spyre Therapeutics director Jeffrey W. Albers sold about 18,000 shares in open-market transactions under a 10b5-1 plan, worth ~$1.88M.
Likely limited near-term impact; any effect would be incremental and quickly absorbed.
The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, which typically reduces the signal strength versus discretionary sales.
Market effects
No clear sector read-through from a single director sale under 10b5-1.
None indicated.
None indicated.
Counterpoint
Because the sale is 10b5-1 pre-arranged, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure (SYRE).
- insiderJeffrey W. Albers
Director who sold shares under a 10b5-1 plan.
